Meeting
2024 ASCO Genitourinary Cancers Symposium
Effect of concomitant medications on treatment response and survival in de novo metastatic prostate cancer: Secondary analysis of the LATITUDE study.
Authors
Soumyajit Roy
Rush University Medical Center, Chicago, IL
Soumyajit Roy , Fred Saad , Rishav Akilla , Yilun Sun , Daniel Eidelberg Spratt , Amar Upadhyaya Kishan , Shawn Malone , Christopher J.D. Wallis , Scott C. Morgan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 120)
DOI
10.1200/JCO.2024.42.4_suppl.120
Abstract #
120
Poster Bd #
E13
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Real-world survival of men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with abiraterone acetate (Abi) or docetaxel (Doc) and comparison with clinical trial outcomes.
First Author: Daniel M. Geynisman
Poster
2024 ASCO Genitourinary Cancers Symposium
Cost-effectiveness of triplet therapies in metastatic hormone-sensitive prostate cancer used in PEACE-1 and ARASENS.
First Author: Nataniel Hernan Lester-Coll
Poster
2023 ASCO Annual Meeting
Association of dynamic changes in serological markers with survival in de novo metastatic hormone-sensitive prostate cancer.
First Author: Soumyajit Roy
First Author: Elena Castro